Abstract
Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United States yearly. No curative therapies are available for metastatic RCC. Improved methods of imaging metastatic RCC would be of value in identifying sites of occult disease and potentially for judging response to therapy. A 58-year-old male with known metastatic clear cell RCC was imaged with both 18F-FDG and 18F-DCFPyL PET/CT. 18F-DCFPyL is a small molecule inhibitor of the prostate-specific membrane antigen (PSMA), a target known to be highly expressed on solid tumor neovasculature. Relative to 18F-FDG, 18F-DCFPyL identified more lesions and demonstrated higher tumor radiotracer uptake.
Keywords: Metastatic renal cell carcinoma, prostate-specific membrane antigen (PSMA), PET/CT
Acknowledgments
Funding: Buerger Family Scholarship Fund, EB006351, CA134675, CA184288, CA103175, CA183031.
Footnotes
Disclosures: No conflicts of interest to disclose by any of the authors.
References
- 1.Cho SY, Gage KL, Mease RC, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med. 2012;53:1883–1891. doi: 10.2967/jnumed.112.104661. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Eiber M, Maurer T, Souvatglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:688–674. doi: 10.2967/jnumed.115.154153. [DOI] [PubMed] [Google Scholar]
- 3.Szabo Z, Mena E, Rowe SP, et al. Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015 doi: 10.1007/s11307-015-0850-8. Epub ahead of print. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Rowe SP, Gage KL, Faraj SF, et al. 18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer. J Nucl Med. 2015 doi: 10.2967/jnumed.115.154336. Epub ahead of print. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Demirci E, Ocak M, Kabasakal L, et al. 68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461–1462. doi: 10.1007/s00259-014-2766-y. [DOI] [PubMed] [Google Scholar]
- 6.Sathekge M, Modiselle M, Vorster M, et al. 68Ga-PSMA imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2015 doi: 10.1007/s00259-015-3066-x. Epub ahead of print. [DOI] [PubMed] [Google Scholar]
- 7.Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5:2674–2681. [PubMed] [Google Scholar]
- 8.Baccala A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007;70:385–390. doi: 10.1016/j.urology.2007.03.025. [DOI] [PubMed] [Google Scholar]